Multispecies minimal physiologically based pharmacokinetic-pharmacodynamic model of antisense oligonucleotides for central nervous system disorders
Drug Metabolism and Disposition · 2025
DOI: 10.1016/j.dmd.2025.100167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Devam A Desai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacokinetics-Pharmacodynamics and Systems Pharmacology, Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, …. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Central Nervous System Diseases, Models, Biological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: University at Buffalo Center for Protein Therapeutics, University at Buffalo, State University of New York.
Abstract (Originalsprache)
Antisense oligonucleotides (ASOs) are selective small biological drugs used to decrease targeted proteins by suppressing mRNA expression. In this study, a quantitative framework was developed to characterize the disposition and effects of such drugs in the central nervous system across species to facilitate the translation of preclinical pharmacology to the clinic. A minimal physiologically based pharmacokinetic (PK)-pharmacodynamic (PD) model for ASOs was developed using published drug and species-specific physiological information, including PK of nusinersen and preclinical PK and mRNA expression for an investigational compound targeting glutamate receptor subunit 1. The model describes relevant pharmacological processes, including (1) clathrin-dependent/independent endocytosis, (2) exocytosis, (3) exonuclease metabolism, (4) macropinocytosis, and (5) knockdown of the targeted protein. Most physiological values were obtained from literature, and drug-specific parameters were estimated. The model captured PK data in preclinical species (mice, rats, and monkeys), infants, and pediatric subjects from phase 1 and 2 studies. Renal clearances were fixed to 2.07, 25.2, 170.7, and 405 mL/h for mice, rats, monkeys, and humans, which were based on prior published values for oligonucleotides. Glutamate receptor subunit 1 mRNA and protein expression in rats were well characterized using a precursor-dependent indirect response model assuming maximal inhibition (Imax) set to 1. Overall, the biodistribution of 2 ASOs across species were characterized by implementing allometric scaling and minimal physiologically based PK concepts. The final model provides insights into the role of specific disposition processes in controlling ASO PK-PD properties in the central nervous system. SIGNIFICANCE STATEMENT: Antisense oligonucleotides enable central nervous system-targeted gene therapy and precision medicine. Using a translational multispecies minimal physiologically based PK-PD model, drug- and system-specific factors were identified that influence the biodistribution of antisense oligonucleotides in preclinical species and humans. The final model can readily translate preclinical data to anticipate human drug exposures in the brain and plasma, help in lead and backup compound selection, project first-in-human dose levels, interpret early human PK-PD data, and facilitate the identification of recommended phase 2 doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacokinetics-Pharmacodynamics and Systems Pharmacology, Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York.
- Division of Pharmacokinetics-Pharmacodynamics and Systems Pharmacology, Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York; Enhanced Pharmacodynamics, LLC, Buffalo, New York. Electroni…
Förderung
- University at Buffalo Center for Protein Therapeutics
- University at Buffalo
- State University of New York
Zitieren
APA
Desai, D. A., Ette, M. E., Shah, D. K., & Mager, D. E. (2025). Multispecies minimal physiologically based pharmacokinetic-pharmacodynamic model of antisense oligonucleotides for central nervous system disorders. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100167
Vancouver
Desai DA, Ette ME, Shah DK, Mager DE. Multispecies minimal physiologically based pharmacokinetic-pharmacodynamic model of antisense oligonucleotides for central nervous system disorders. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100167
BibTeX
@article{Desai2025,
author = {Desai, Devam A and Ette, Mfonabasi E and Shah, Dhaval K and Mager, Donald E},
title = {Multispecies minimal physiologically based pharmacokinetic-pharmacodynamic model of antisense oligonucleotides for central nervous system disorders},
journal = {Drug Metabolism and Disposition},
year = {2025},
doi = {10.1016/j.dmd.2025.100167}
}
EUVIMED